Literature DB >> 1383822

A role for hepatitis C virus infection in type II cryoglobulinemia.

V Agnello1, R T Chung, L M Kaplan.   

Abstract

BACKGROUND: Type II cryoglobulinemia is a vasculitis characterized by cryoglobulins consisting of complexes of polyclonal IgG and monoclonal IgM rheumatoid factors. The cause of these immune complexes is unknown, though both the hepatitis B (HBV) and C (HCV) viruses have been suspected.
METHODS: We studied 19 patients with Type II cryoglobulinemia for markers of HCV and HBV infection. Quantitative HCV antibody and RNA studies were performed on whole serum, cryoprecipitates, and supernatants.
RESULTS: Eight patients (42 percent) had HCV antibodies, and 16 (84 percent) had HCV RNA: Of the 19 patients, 5 (26 percent) had HBV markers, but only 1 had evidence of active HBV infection. Control serum samples from nine patients with Type I cryoglobulinemia were negative for HCV antibody and HCV RNA: There was a close, although not exclusive, association of one type of rheumatoid factor (WA) with HCV RNA: HCV antibody and HCV RNA were concentrated approximately 10-fold and 1000-fold, respectively, in the Type II cryoglobulins examined.
CONCLUSIONS: Type II cryoglobulinemia is strongly associated with concomitant HCV infection and a high rate of false negative serologic tests. HCV virions and HCV antigen-antibody complexes are concentrated in the cryoprecipitates, most commonly in association with the WA type of rheumatoid factor, suggesting a role for HCV in the pathogenesis of mixed cryoglobulinemia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1383822     DOI: 10.1056/NEJM199211193272104

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  216 in total

Review 1.  Molecular diagnostic approach to non-Hodgkin's lymphoma.

Authors:  D A Arber
Journal:  J Mol Diagn       Date:  2000-11       Impact factor: 5.568

2.  Mixed cryoglobulinaemia after hepatitis C virus: more and less ambiguity.

Authors:  V Agnello
Journal:  Ann Rheum Dis       Date:  1998-12       Impact factor: 19.103

Review 3.  Hepatitis C virus infection and lymphoproliferative disorders.

Authors:  L R Peña; S Nand; N De Maria; D H Van Thiel
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

Review 4.  Management of virus-induced systemic vasculitides.

Authors:  Loïc Guillevin; Pascal Cohen
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

5.  Whole-blood hepatitis C virus RNA extraction methods.

Authors:  W Schmidt; J T Stapleton
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

6.  Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor.

Authors:  S Wünschmann; J D Medh; D Klinzmann; W N Schmidt; J T Stapleton
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia.

Authors:  G Lake-Bakaar; I Jacobson; A Talal
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

Review 8.  Primary, post-primary and non-specific immunoglobulin M responses in HCV infection.

Authors:  Lynn B Dustin; Edgar D Charles
Journal:  Antivir Ther       Date:  2012-12-07

9.  Antiviral treatment down-regulates peripheral B-cell CD81 expression and CD5 expansion in chronic hepatitis C virus infection.

Authors:  Eli Zuckerman; Aharon Kessel; Gleb Slobodin; Edmond Sabo; Daniel Yeshurun; Elias Toubi
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 10.  Renal dysfunction associated with liver transplantation.

Authors:  R M Jindal; I Popescu
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.